Breast Cancer Info Now on Internet
NEW YORK--Women seeking information about breast cancer can now turn to their computers. The National Alliance of Breast Cancer Organizations (NABCO) has established the first nonprofit organization breast cancer web site (http://www.nabco.org) to provide In-ternet users with up-to-date information about the latest research, current treatment options, support services, and links to other Internet sites.
NEW YORK--Women seeking information about breast cancer can nowturn to their computers. The National Alliance of Breast CancerOrganizations (NABCO) has established the first nonprofit organizationbreast cancer web site (http://www.nabco.org) to provide In-ternetusers with up-to-date information about the latest research, currenttreatment options, support services, and links to other Internetsites.
The NABCO web site, initially supported through an educationalgrant from Rhône-Poulenc Rorer Oncology, has 10 separateareas within its own Home Page and links to other breast health-relatedsites.
Some of the areas that users of NABCO's Home Page will be ableto access include What's New, updated weekly; NABCO's latest factsheets; articles from NABCO News; legislative action notices;NABCO's events calendar; nationwide support groups; surveys aboutcurrent issues; NABCO resources; e-mail to NABCO's informationspecialists who answer questions about breast cancer; and informationabout how to join NABCO.
NABCO's debut on the Internet is part of an overall effort toexpand the organization's information and education programs.For more information about NABCO services, call 800-719-9154.
Experts Discuss Differences in Radiotherapy Outcomes in BRCA+ Breast Cancer
October 30th 2023Rebecca M. Shulman, MD, and Zachary Kiss, DO, discuss findings from a study evaluating differences in outcomes with radiotherapy and disease characteristics of patients with breast cancer harboring BRCA mutations compared with those without mutated disease.
FDA Approves Capivasertib Plus Fulvestrant in Advanced HR+, HER2– Breast Cancer
November 16th 2023Patients with locally advanced or metastatic breast cancer that is hormone receptor–positive, HER2-negative breast cancer with 1 or more PIK3CA, AKT1, or PTEN alterations may now receive capivasertib plus fulvestrant.
Oncology On-The-Go Podcast: De-escalating Breast Cancer Treatment
May 8th 2023Rakhshanda Rahman, MD, FRCS, FACS, emphasizes the importance of educating patients and physicians on the potential risks and benefits of new approaches and technologies involved in the de-escalation of breast cancer treatment.
